New cancer drug enters first human trials
NCT ID NCT07391644
Summary
This is the first study testing the experimental drug JSKN027 in people with advanced solid tumors that have stopped responding to standard treatments. Researchers will give increasing doses to 250 patients to check for safety, side effects, and early signs that the drug might help shrink tumors. The study will focus on specific cancers including colorectal cancer, lung cancer, and liver cancer in later stages.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.